Myeloperoxidase improves risk stratification in patients with ischemia and normal cardiac troponin I concentrations

Clinical Chemistry

Volumn 57, Issue 4, 2011, Pages 603-608

  Apple, Fred S ^a   Smith, Stephen W ^a   Pearce, Lesly A ^b   Schulz, Karen M ^a   Ler, Ranka ^a   Murakami, MaryAnn M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Biostatistical Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOPEROXIDASE; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTERMETHOD COMPARISON; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLASMA; PROTEIN BLOOD LEVEL;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PEROXIDASE; TROPONIN I;

EID: 79956133197     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.158014     Document Type: Article

References (21)

1. Micheel CM, Ball JR. Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington, DC: National Academies Press; 2010. p 1-314.
2. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005;25:1102-11. (Pubitemid 40776595)
3. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;50:159-65. (Pubitemid 47002189)
4. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-42. (Pubitemid 34041599)
5. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al., on behalf of the CAPTURE investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5.
6. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604. (Pubitemid 37288567)
7. Esporcatte R, Rey HC, Rangel FO, Rocha RM, Mendonca Filho HT, Dohmann HF, Albanesi FM. Predictive value of myeloperoxidase to identify high risk patients admitted to the hospital with acute chest pain. Arq Bras Cardiol 2007;89:377-84.
8. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008;29:1096-102.
9. Eggers KM, Dellborg M, Johnston N, Oldgren J, Swahn E, Venge P, Lindahl B. Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin Biochem 2010;43:240-5.
10. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007;53:874-81. (Pubitemid 46744243)
11. Shah KB, Kop WJ, Christenson RH, Diercks DB, Kuo D, Henderson S, et al. Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients with dyspnea. Clin Chem 2009;55:59-67.
12. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49:1993-2000. (Pubitemid 46734639)
13. Shih J, Datwyler SA, Hsu SC, Matias MS, Pacenti DP, Lueders C, et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem 2008;54:1076-9. (Pubitemid 351793416)
14. Scheffer PG, van der Zwan LP, Schindhelm RK, Vermue HPA, Teerlink T. Myeloperoxidase concentrations in EDTA-plasma of healthy subjects are discordant with concentrations in heparin-plasma and serum. Clin Biochem 2009;42:1490-2.
15. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38.
16. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, et al., on behalf of the Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810-24.
17. Dominguez-Rodriguez A, Samimi-Fard S, Abru-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Prognostic value of admission myeloperoxidase levels in patients with ST-elevation myocardial infarction and cardiogenic shock. Am J Cardiol 2008;101:1537-40.
18. Wong ND, Gransar H, Narula J, Shaw L, Moon JH, Miranda-Peats R, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging 2009;2:1093-9.
19. Kubala L, Lu G, Baldus S, Berglund L, Eiserich JP. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta 2008;394:59-62.
20. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem 2009;55:1462-70.
21. Morrow DA. Appraisal of myeloperoxidase for evaluation of patients with suspected acute coronary syndromes. J Am Coll Cardiol 2007;49:2001-2.